Lupin has reported results for the first quarter ended June 30, 2013.
On standalone basis, the company has posted a rise of 14.92% in its net profit at Rs 410.55 crore for the quarter ended June 30, 2013 as compared to Rs 357.23 crore for the same quarter in the previous year. Total income has increased by 9.97% at Rs 1983.32 crore for quarter under review as compared to Rs 1803.37 crore for the quarter ended June 30, 2012.
On consolidated basis, the Group has posted a rise of 43.03% in its net profit at Rs 401.06 crore for the quarter ended June 30, 2013 as compared to Rs 280.39 crore for the same quarter in the previous year. Total income has increased by 13.16% at Rs 2577.11 crore for quarter under review as compared to Rs 2277.30 crore for the quarter ended June 30, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: